News on Medial

Legaltech startup LegalKart raises Rs 6.5 Cr in fresh round

EntrackrEntrackr ยท 1y ago
Legaltech startup LegalKart raises Rs 6.5 Cr in fresh round
Medial

LegalKart, a legal consultation platform, raised Rs 6.5 crore in its latest funding round from IIM Udaipur Incubation Centre. Aevitas Capital, Shift Alt Cap, and others have also participated. Earlier in January 2022, the Gurugram-based startup had raised Rs 4 crore in its pre-Series A round led by Mumbai Angels and others. The proceeds will be infused to ramp up companyโ€™s growth and drive the development of its AI-enabled legal technology solutions. Founded in 2019 by Arvind Singhatiya, LegalKart provides legal services with AI-driven documentation, consultations, and tailored digital solutions. The platform allows users to connect with legal professionals and lawyers in all Indian languages through audio and video calls, ensuring greater accessibility. LegalKart goes beyond consultations, offering services like property document verification, vehicle challan payments, and convenient review and drafting of legal documents. In the last 8 months, LegalKart claims to have witnessed a 453% jump in its business topline. The newly infused funds will be strategically utilized to fuel this exponential growth, introduce new AI-driven products, and expand LegalKartโ€™s presence in Indiaโ€™s tier II and tier III cities.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr ยท 6m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IANโ€™s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditionsโ€”ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.